Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
BMC Complement Altern Med ; 15: 78, 2015 Mar 24.
Article in English | MEDLINE | ID: mdl-25886934

ABSTRACT

BACKGROUND: Low-level lasers working at 633 or 670 nm and emitting extremely low power densities (Ultra Low Level Lasers - ULLL) exert an overall effect of photobiostimulation on cellular metabolism and energy balance. In previous studies, it was demonstrated that ULLL pulsed emission mode regulates neurite elongation in vitro and exerts protective action against oxidative stress. METHODS: In this study the action of ULLL supplied in both pulsed and continuous mode vs continuous LLL on fibroblast cultures (Mouse Embryonic Fibroblast-MEF) was tested, focusing on mitochondria network and the expression level of mRNA encoding for proteins involved in the cell-matrix adhesion. RESULTS: It was shown that ULLL at 670 nm, at extremely low average power output (0.21 mW/ cm(2)) and dose (4.3 mJ/ cm(2)), when dispensed in pulsed mode (PW), but not in continuous mode (CW) supplied at both at very low (0.21 mW/cm(2)) and low levels (500 mW/cm(2)), modifies mitochondria network dynamics, as well as expression level of mRNA encoding for selective matrix proteins in MEF, e.g. collagen type 1α1 and integrin α5. CONCLUSIONS: We suggest that pulsatility, but not energy density, is crucial in regulating expression level of collagen I and integrin α5 in fibroblasts by ULLL.


Subject(s)
Extracellular Matrix/metabolism , Fibroblasts/radiation effects , Lasers , Light , Low-Level Light Therapy , Mitochondria/metabolism , Oxidative Stress , Animals , Collagen/metabolism , Fibroblasts/metabolism , Integrin alpha5/metabolism , Mice , RNA, Messenger/metabolism
2.
Neurobiol Dis ; 70: 53-68, 2014 Oct.
Article in English | MEDLINE | ID: mdl-24952363

ABSTRACT

Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have been identified in a neurodevelopmental disorder characterized by early-onset intractable seizures, severe developmental delay, intellectual disability, and Rett's syndrome-like features. Since the physiological functions of CDKL5 still need to be elucidated, in the current study we took advantage of a new Cdkl5 knockout (KO) mouse model in order to shed light on the role of this gene in brain development. We mainly focused on the hippocampal dentate gyrus, a region that largely develops postnatally and plays a key role in learning and memory. Looking at the process of neurogenesis, we found a higher proliferation rate of neural precursors in Cdkl5 KO mice in comparison with wild type mice. However, there was an increase in apoptotic cell death of postmitotic granule neuron precursors, with a reduction in total number of granule cells. Looking at dendritic development, we found that in Cdkl5 KO mice the newly-generated granule cells exhibited a severe dendritic hypotrophy. In parallel, these neurodevelopmental defects were associated with impairment of hippocampus-dependent memory. Looking at the mechanisms whereby CDKL5 exerts its functions, we identified a central role of the AKT/GSK-3ß signaling pathway. Overall our findings highlight a critical role of CDKL5 in the fundamental processes of brain development, namely neuronal precursor proliferation, survival and maturation. This evidence lays the basis for a better understanding of the neurological phenotype in patients carrying mutations in the CDKL5 gene.


Subject(s)
Dendrites/physiology , Glycogen Synthase Kinase 3/metabolism , Neurons/physiology , Protein Serine-Threonine Kinases/deficiency , Proto-Oncogene Proteins c-akt/metabolism , Animals , Apoptosis/physiology , Cell Enlargement , Cell Survival/physiology , Cells, Cultured , Dentate Gyrus/growth & development , Dentate Gyrus/physiology , Female , Glycogen Synthase Kinase 3 beta , Male , Maze Learning/physiology , Mice, Knockout , Neural Stem Cells/physiology , Neurogenesis/physiology , Protein Serine-Threonine Kinases/genetics , Signal Transduction
3.
Curr Top Med Chem ; 13(15): 1843-52, 2013.
Article in English | MEDLINE | ID: mdl-23931439

ABSTRACT

The drug discovery for disease-modifying agents in Alzheimer disease (AD) is facing a failure of clinical trials with drugs based on two driving hypotheses, i.e. the cholinergic and amyloidogenic hypotheses. In this article we recapitulate the main aspects of AD pathology, focusing on possible mechanisms for synaptic dysfunction, neurodegeneration and inflammation. We then present the pharmacological and neurobiological profile of a novel compound (CHF5074) showing both anti-inflammatory and gamma-secretase modulatory activities, discussing the possible time-window for effective treatment in an AD transgenic mouse model. Finally, the concept of cognitive reserve is introduced as possible target for preventive therapies.


Subject(s)
Alzheimer Disease/drug therapy , Anti-Inflammatory Agents/chemical synthesis , Cyclopropanes/chemical synthesis , Enzyme Inhibitors/chemical synthesis , Flurbiprofen/analogs & derivatives , Nootropic Agents/chemical synthesis , Alzheimer Disease/metabolism , Alzheimer Disease/physiopathology , Amyloid Precursor Protein Secretases/antagonists & inhibitors , Amyloid Precursor Protein Secretases/metabolism , Animals , Anti-Inflammatory Agents/therapeutic use , Cyclopropanes/therapeutic use , Drug Design , Enzyme Inhibitors/therapeutic use , Flurbiprofen/chemical synthesis , Flurbiprofen/therapeutic use , Humans , Inflammation/drug therapy , Mice , Mice, Transgenic , Nootropic Agents/therapeutic use , Synapses/drug effects , Synapses/pathology , Synaptic Transmission/drug effects , Translational Research, Biomedical
SELECTION OF CITATIONS
SEARCH DETAIL
...